Abstract:Abstract 785 Introduction: The ability of allogeneic T cells to effect anti tumor responses had greatly improved the outcome of malignant EBV-associated lymphoproliferations. But high doses of DLI (donor lymphocyte infusion) could arise severe GVHD (graft versus host disease), and affect clinical outcomes. Recently, we successfully treated four EBV-associated lymphoma children with high doses of DLI from their IPA (inherited paternal antigens)-positive mothers, with no obvious GVHD occurred, which indicated that high doses of maternal leukocytes infusions could be an effective and safe therapy for EBV-associated lymphoma. Epstein-Barr virus (EBV) associated lymphoproliferative disorders(LPD) or hemophagocyticlymphohistiocytosis(EBV-HLH) in pediatric patients is classified into malignant lymphoma due to 2008 WHO International Working Formulation for lymphoma classification. In pediatric patients, cure is rarely get through conventional therapy such as chemotherapy. Approaches using adoptive immunotherapies offer very attractive alternative options for this subgroup of patients. The rationale for this strategy was that most EBV seropositive individuals have a high frequency of EBV specific precursors so that transfer of unmanipulated donor lymphocyte populations should be able to restore the immune response to EBV. However, these products may also contain a high frequency of alloreactive T cells so there is a significant risk of GVHD. Reciprocal cell traffic between mother and fetus during pregnancy gives rise to long-term postpartum fetal–maternal lympho-hematopoietic microchimerism (MC). Recent experimental evidence have suggested the association of MC with acquired immunologic hyporesponsiveness, which would benefit solid organ and hematopoietic stem cell transplantation. Some research have showed that mother-to-child transplantations involved significantly less GVHD and better outcome than father-to-child transplantations. Based on this fetal-maternal tolerance theory, we treated four EBV-associated lymphoma children with high doses of DLI from their mothers. Material and methods: Our four patients were all developed with fever over than 6 months, accompanied with lymphadenopathy, hepatosplenomegaly, two of them with skin lesion. The diagnosis were confirmed by skin or lymphnode biopsies. EBV-DNA is positive in all of the patients9 plasma at the quantitation of >1×10 4 copies /ml. One of the patient had accepted chemotherapy in the past but got no remission. Using sex determining region Y chromosome (SRY) gene and insertion-deletion (InDel) polymorphism as fetal markers, child9s DNA (IPAs) were detected through nested PCR and QT-PCR technology in all of the four mothers9 blood at the level of 1: 10 4 -10 5 . With the approval of Ethics Committee, we treated these patients with infusions of unmanipulated leukocytes from their HLA-haploidentical, EBV-seropositive mothers. First at the doses below 10 7 PBNC cells/kg, while no side effects occurred, we began infusing high doses of mother9s PBMC at above 10 8 PBNC cells /kg per time. Results: Clinical remissions were achieved in all of the patients within 3 to 10 days after the infusions, with remarkable reduction of the lymphnode and spleen, the EBV-DNA were undetectable in the patients9 plasma. The remissions were sustained without further therapy for 5-10 months except one patient who got recurrance of lymphadenopathy and fever about two months after each infusion. We had monitored the quantitation of his mother9s lymphocyte in the child9s blood and found no detectable maternal MC a week after the infusion. During the process, none of our patients developed obvious GVHD. Conclusions: High doses of maternal lymphocyte infusions could be an effective and safe treatment for EBV-associated lymphoma. Further research is needed to improve the sustained effect. Disclosures: No relevant conflicts of interest to declare.

Treatment of a B‐cell lymphoproliferative disorder in a liver transplant patient with interferon alfa and gamma globulin: A case report

[Post-transplant EBV-associated lymphoproliferative disorders--report of two cases]

[Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia]

Case Report: A Case of Epstein-Barr Virus-Associated Acute Liver Failure Requiring Hematopoietic Cell Transplantation After Emergent Liver Transplantation

Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas

Nivolumab Treatment of Relapsed/refractory Epstein-Barr Virus–associated Hemophagocytic Lymphohistiocytosis in Adults

Extracorporeal photopheresis: A case of graft-versus-host-disease and hemophagocytic lymphohistiocytosis following liver transplantation

Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease

Antiviral prophylaxis and the Epstein Barr virus‐related post‐transplant lymphoproliferative disorder

[Early Diagnosis and Comprehensive Treatments of Post-Transplantation Lymphoproliferative Disorder after Pediatric Liver Transplantation].

Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation

Impact of EBV Infection and Immune Function Assay for Lymphoproliferative Disorder in Pediatric Patients after Liver Transplantation: A Single-Center Experience.

Epstein-Barr Virus-Negative Plasmablastic Lymphoma Post-liver Transplantation

Gastrointestinal Tract Post-Transplant Lymphoproliferative Disorder after Liver Transplantation

High Doses of Moternal Lymphocyte Infusions to Treat EBV-Associated Lymphoma in Pediatric Patients.

Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation

Posttransplant Lymphoproliferative Disorder in a Patient With Alpha-1 Antitrypsin Deficiency: A Case Report

Correction of DiGeorge Anomaly with EBV-Induced Lymphoma by Transplantation of Organ-Cultured Thymus and Epstein–Barr-Specific Cytotoxic T Lymphocytes

Immunosuppressant Indulges EBV Reactivation and Related Lymphoproliferative Disease by Inhibiting Vδ2+T Cells Activities after Hematopoietic Transplantation for Blood Malignancies

A Rare Case of Systemic Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis in an Immunocompetent Young Man: Potential Diagnostic Pitfall and Therapeutic Challenge

Outcome of Brain Lymphoma in a High Epstein-Barr Virus-Prevalence Country After Kidney Transplantation